Sanofi-Aventis Sues Apotex Over ANDA For Eloxatin

Law360, New York (August 29, 2008, 12:00 AM EDT) -- Sanofi-Aventis has targeted Canada's Apotex Corp. in its latest effort to keep a generic version of colon cancer drug Eloxatin off the market in the United States.

In a complaint filed Wednesday in the U.S. District Court for the District of New Jersey, the French drugmaker claims Apotex's abbreviated new drug application with the U.S. Food and Drug Administration to make generic Eloxatin constitutes infringement of U.S. Patent Number 5,338,874.

The '874 patent is listed in the FDA's Orange Book for Eloxatin. Sanofi-Aventis licenses the patent...
To view the full article, register now.